ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2010

Category: .

ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2010

ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:
Rheumatoid Arthritis (RA)
Polyarticular Juvenile Idiopathic Arthritis (PJIA)
idiopathic arthritis.
Systemic Juvenile Idiopathic Arthritis (SJIA)
Intravenous Infusion
Injection: 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL),
400 mg/20 mL (20 mg/mL) in single-dose vials for further dilution prior to
intravenous infusion
Subcutaneous Injection
Injection: 162 mg/0.9 mL in a single-dose prefilled syringe or single-dose
prefilled ACTPen® autoinjector
Manufactured By: Genentech
Prescribing Information URL: Click Here

Access to ACTEMRA ® (tocilizumab) injection: All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.